SGLT2 inhibitors and non-paroxysmal AF Recent studies have shown that sodium dependent glucose cotransporter 2 inhibitors have beneficial effects reducing the risk of incident AF and improving AF prognosis [49–52]. This evidence concerns the gene SLC5A2 and Paroxysmal atrial fibrillation.